JP2019178177A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019178177A5 JP2019178177A5 JP2019137721A JP2019137721A JP2019178177A5 JP 2019178177 A5 JP2019178177 A5 JP 2019178177A5 JP 2019137721 A JP2019137721 A JP 2019137721A JP 2019137721 A JP2019137721 A JP 2019137721A JP 2019178177 A5 JP2019178177 A5 JP 2019178177A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- administration
- oral
- continuous infusion
- cangrelor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 13
- 238000001802 infusion Methods 0.000 claims 7
- 229960001080 cangrelor Drugs 0.000 claims 6
- PAEBIVWUMLRPSK-IDTAVKCVSA-N cangrelor Chemical compound C1=NC=2C(NCCSC)=NC(SCCC(F)(F)F)=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)C(Cl)(Cl)P(O)(O)=O)[C@@H](O)[C@H]1O PAEBIVWUMLRPSK-IDTAVKCVSA-N 0.000 claims 6
- 229960002528 ticagrelor Drugs 0.000 claims 5
- OEKWJQXRCDYSHL-FNOIDJSQSA-N ticagrelor Chemical compound C1([C@@H]2C[C@H]2NC=2N=C(N=C3N([C@H]4[C@@H]([C@H](O)[C@@H](OCCO)C4)O)N=NC3=2)SCCC)=CC=C(F)C(F)=C1 OEKWJQXRCDYSHL-FNOIDJSQSA-N 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 238000013146 percutaneous coronary intervention Methods 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims 1
- 239000005465 B01AC22 - Prasugrel Substances 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 229960003009 clopidogrel Drugs 0.000 claims 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 238000011866 long-term treatment Methods 0.000 claims 1
- 229960004197 prasugrel Drugs 0.000 claims 1
- DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 claims 1
- 239000008354 sodium chloride injection Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/792,056 | 2013-03-09 | ||
| US13/792,056 US9427448B2 (en) | 2009-11-11 | 2013-03-09 | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| US201361815735P | 2013-04-25 | 2013-04-25 | |
| US61/815,735 | 2013-04-25 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017197488A Division JP2018002739A (ja) | 2013-03-09 | 2017-10-11 | 虚血性事象を処置し、その発生率を低減させ、かつ／または予防する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019178177A JP2019178177A (ja) | 2019-10-17 |
| JP2019178177A5 true JP2019178177A5 (enExample) | 2019-12-26 |
| JP6840197B2 JP6840197B2 (ja) | 2021-03-10 |
Family
ID=51537409
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561314A Active JP6247708B2 (ja) | 2013-03-09 | 2013-05-29 | 虚血性事象を処置し、その発生率を低減させ、かつ／または予防する方法 |
| JP2017197488A Withdrawn JP2018002739A (ja) | 2013-03-09 | 2017-10-11 | 虚血性事象を処置し、その発生率を低減させ、かつ／または予防する方法 |
| JP2019137721A Active JP6840197B2 (ja) | 2013-03-09 | 2019-07-26 | 虚血性事象を処置し、その発生率を低減させ、かつ／または予防する方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561314A Active JP6247708B2 (ja) | 2013-03-09 | 2013-05-29 | 虚血性事象を処置し、その発生率を低減させ、かつ／または予防する方法 |
| JP2017197488A Withdrawn JP2018002739A (ja) | 2013-03-09 | 2017-10-11 | 虚血性事象を処置し、その発生率を低減させ、かつ／または予防する方法 |
Country Status (10)
| Country | Link |
|---|---|
| EP (2) | EP3978002A1 (enExample) |
| JP (3) | JP6247708B2 (enExample) |
| CN (2) | CN115120606A (enExample) |
| AU (1) | AU2013381855B2 (enExample) |
| BR (1) | BR112015022070B1 (enExample) |
| CA (1) | CA2904523C (enExample) |
| EA (1) | EA034550B1 (enExample) |
| ES (1) | ES2904256T3 (enExample) |
| PL (1) | PL2964233T3 (enExample) |
| WO (1) | WO2014143107A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA034550B1 (ru) * | 2013-03-09 | 2020-02-19 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Способы лечения, снижения частоты и/или профилактики ишемических событий |
| WO2018234565A1 (en) * | 2017-06-23 | 2018-12-27 | Chiesi Farmaceutici S.P.A. | Method of preventing of systemic-to-pulmonary-artery shunt thrombosis |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU679721B2 (en) | 1993-02-10 | 1997-07-10 | Astrazeneca Ab | N-alkyl-2-substituted ATP analogues |
| SE9604795D0 (sv) | 1996-12-20 | 1996-12-20 | Astra Pharma Prod | New pharmaceutical formulation |
| SE9702680D0 (sv) | 1997-07-11 | 1997-07-11 | Astra Pharma Prod | New formulation |
| SE9904377D0 (sv) | 1999-12-01 | 1999-12-01 | Astra Pharma Prod | Pharmaceutical combinations |
| US9427448B2 (en) * | 2009-11-11 | 2016-08-30 | The Medicines Company | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| WO2009140092A1 (en) * | 2008-05-13 | 2009-11-19 | The Medicines Company | Maintenance of platelet inhibition during antiplatelet therapy |
| US20100297675A1 (en) * | 2008-11-24 | 2010-11-25 | Huayun Deng | Substrate and method for culturing breast cells |
| CA2747310C (en) * | 2008-12-30 | 2018-02-06 | Thrombologic Aps | Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof |
| SG176295A1 (en) * | 2009-06-16 | 2012-01-30 | Cardoz Ab | Crystalline form of pemirolast |
| WO2011060066A2 (en) * | 2009-11-11 | 2011-05-19 | The Medicines Company | Methods of treating or preventing stent thrombosis |
| EA034550B1 (ru) * | 2013-03-09 | 2020-02-19 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Способы лечения, снижения частоты и/или профилактики ишемических событий |
-
2013
- 2013-05-29 EA EA201591683A patent/EA034550B1/ru unknown
- 2013-05-29 EP EP21205348.2A patent/EP3978002A1/en active Pending
- 2013-05-29 WO PCT/US2013/043136 patent/WO2014143107A1/en not_active Ceased
- 2013-05-29 BR BR112015022070-3A patent/BR112015022070B1/pt active IP Right Grant
- 2013-05-29 CN CN202210682855.1A patent/CN115120606A/zh active Pending
- 2013-05-29 EP EP13878203.2A patent/EP2964233B1/en active Active
- 2013-05-29 CA CA2904523A patent/CA2904523C/en active Active
- 2013-05-29 CN CN201380076382.XA patent/CN106102750A/zh active Pending
- 2013-05-29 PL PL13878203T patent/PL2964233T3/pl unknown
- 2013-05-29 JP JP2015561314A patent/JP6247708B2/ja active Active
- 2013-05-29 ES ES13878203T patent/ES2904256T3/es active Active
- 2013-05-29 AU AU2013381855A patent/AU2013381855B2/en active Active
-
2017
- 2017-10-11 JP JP2017197488A patent/JP2018002739A/ja not_active Withdrawn
-
2019
- 2019-07-26 JP JP2019137721A patent/JP6840197B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0893998B2 (en) | Colonic delivery of nicotine to treat inflammatory bowel disease | |
| JP2023088944A5 (enExample) | ||
| US11607389B2 (en) | Delayed release deferiprone tablets and methods of using the same | |
| JP2025020134A5 (enExample) | ||
| JP2019501881A5 (enExample) | ||
| JP2019178177A5 (enExample) | ||
| CN113274384B (zh) | 驴食草酚在制备防治溃疡性结肠炎的药物中的应用及其药物 | |
| JP2016505050A5 (enExample) | ||
| JP2022035920A5 (enExample) | ||
| JP2020510043A5 (enExample) | ||
| JP2019509309A5 (enExample) | ||
| JP2016510738A5 (enExample) | ||
| EP3937928A1 (en) | Capsid assembly modulator solid formulation | |
| WO2018004498A1 (en) | Nsaid and h2 receptor antagonist combinations for the treatment of pain and inflammation | |
| TW201806599A (zh) | 用於快速開始抗抑鬱作用之給藥方案 | |
| JP7376679B2 (ja) | Ｈｂｖ感染の処置のためのｅｙｐ００１とｉｆｎの相乗効果 | |
| JPWO2021048280A5 (enExample) | ||
| HK40066536B (en) | Synergistic effect of eyp001 and pegylated ifn-alpha for the treatment of hbv infection | |
| HK40066536A (en) | Synergistic effect of eyp001 and pegylated ifn-alpha for the treatment of hbv infection | |
| JPWO2021150559A5 (enExample) | ||
| JPWO2021005129A5 (enExample) | ||
| JPWO2021127308A5 (enExample) | ||
| JPWO2022035752A5 (enExample) |